Hypochondriasis
Methodology & AI Transparency ⓘ
Hypochondriasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hypochondriasis is an ICD-10-CM indexed diagnosis (F45.21) within Depression, Bipolar & Mood Disorders.
- 2 Real-world patient consensus: Federal ICD-10-CM code F45.21 categorizes Hypochondriasis under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Clinicians assessing Hypochondriasis focus on prefrontal-limbic circuit dysregulation [Hypochondriasis F45.21] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Hypochondriasis: maintaining PHQ-9 Symptom Severity in Hypochondriasis (F45.21: Score) within < 4 (clinical remission) (F45.21).
Ask our AI Specialists anything about Hypochondriasis
What Is Hypochondriasis?
Hypochondriasis is an ICD-10-CM indexed diagnosis (F45.21) within Depression, Bipolar & Mood Disorders. Clinical evaluation centers on validated longitudinal mood in Hypochondriasis (F45.21: rating scales (PHQ-9) alongside serial PHQ-9 Symptom Severity in Hypochondriasis (F45.21: Score) tracking (< 4 (clinical remission) (F45.21)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Hypochondriasis (F45.21) features prefrontal-limbic circuit dysregulation [Hypochondriasis F45.21]. therapeutic stabilization in depression & mood is verified against TSH & Free in Hypochondriasis (F45.21: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Hypochondriasis (F45.21): loss of interest in Hypochondriasis (F45.21: or pleasure in)
- • Secondary Hypochondriasis clinical sign: persistent low mood, in Hypochondriasis (F45.21: emotional flatness, or)
- • Symptom flares in Hypochondriasis correlating with PHQ-9 Symptom Severity in Hypochondriasis (F45.21: Score) deviation outside < 4 (clinical remission) (F45.21)
- • Functional depression & mood impact requiring validated longitudinal mood in Hypochondriasis (F45.21: rating scales (PHQ-9) evaluation (F45.21)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hypochondriasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F45.21 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Hypochondriasis (F45.21: Score) | < 4 (clinical remission) (F45.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Hypochondriasis (F45.21: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F45.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Hypochondriasis (F45.21: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F45.21) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hypochondriasis
Treatment selection for Hypochondriasis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hypochondriasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of concurrent anxiety on response to sertraline and imipramine in patients: What a 426-Participant Study Found Despite the chronicity of depressive illness, acute treatment with both sertraline and imipramine significantly improved psychosocial and quality of life measures. Depression and anxiety • 2001-01-15 • Randomized Controlled Trial | N = 426 | 93/100 | PMID 11233456 ↗ |
| What the Latest Evidence Really Says About Comparative efficacy and tolerability of antidepressants for depression in When considering the risk-benefit profile of antidepressants in the acute treatment of depression, these drugs do not seem to offer a clear advantage for children and adolescents. Lancet (London, England) • 2016-08-27 • Meta-Analysis | Multi-cohort | 92/100 | PMID 27289172 ↗ |
| Can This Approach Help? Inside the Latest Research on Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in CYP2C19 polymorphisms had a small and clinically unimportant influence on bupropion minor metabolites and secondary metabolism and no effect on depression or side effect scores. The Journal of pharmacology and experimental therapeutics • 2026-03-15 • Randomized Controlled Trial | N = 70 | 88/100 | PMID 41759239 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Among 126 participants who were randomized (mean [SD] age, 55.3 years [14.9 years]; 78 women [61.9%]), 114 (90.5%) completed the trial. JAMA • 2019-08-20 • Randomized Controlled Trial | N = 64 | 88/100 | PMID 31429896 ↗ |
| Can This Approach Help? Inside the Latest Research on Gold-standard blind, compared against a dummy pill (placebo) evaluation of Side effects were generally mild to moderate and similar between treatment groups. Journal of psychopharmacology (Oxford, England) • 2010-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 19164492 ↗ |
Hypochondriasis Patient Community & “People Like Me” Threads
Filter Hypochondriasis community threads and patient logs by age, biological sex, dosage, and treatment duration.